1-20 of 141 results for answeredby:"James Frith"
Librarians' tools
- Search time
- 0.293 seconds
- Solr query time
- 0.002 seconds
- Search query
- answeredby:"James Frith"
- We searched for
- answeringMember_ses:437165 OR answeringDept_ses:437165 OR askedToReplyAuthor_ses:437165
Type
House
Session
Year
Department
Member
More
Primary member
More
Answering member
Legislative stage
Legislation
Subject
More
Publisher
To ask the Secretary of State for Health and Social Care, what her department’s priorities are for this parliamentary session.
To ask the Secretary of State for Health and Social Care, what her department’s priorities are for this parliamentary session.
The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.
To ask the Secretary of State for Health and Social Care, what steps he is taking to maximise the use of available technologies used to establish the available capacity of NHS dental practices to improve access to NHS dentistry.
To ask the Secretary of State for Health and Social Care, what steps he is taking to maximise the use of available technologies used to establish the available capacity of NHS dental practices to improve access to NHS dentistry.
The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.
To ask the Secretary of State for Health and Social Care, with reference to the Answer of 7 July 2026 to Question 15439, which national clinical guideline or professional standard sets out the requirement for healthcare providers to evaluate a patient's comorbidities, psychiatric history and risk of adverse drug reactions...
To ask the Secretary of State for Health and Social Care, with reference to the Answer of 7 July 2026 to Question 15439, which national clinical guideline or professional standard sets out the requirement for healthcare providers to evaluate a patient's comorbidities, psychiatric history and risk of adverse drug reactions...
The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.
To ask the Secretary of State for Health and Social Care, what assessment her Department has made of the variation between integrated care boards (ICB) in the proportion of patients with cardiovascular disease achieving recommended cholesterol levels; and what steps her Department is taking to support ICBs to improve lipid...
To ask the Secretary of State for Health and Social Care, what assessment her Department has made of the variation between integrated care boards (ICB) in the proportion of patients with cardiovascular disease achieving recommended cholesterol levels; and what steps her Department is taking to support ICBs to improve lipid...
The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.
To ask the Secretary of State for Health and Social Care, what assessment she has made of the potential merits of making adrenaline auto injectors more widely available, such as in restaurants and other public places, in the context of the report from the Commission on Human Medicine in 2021.
To ask the Secretary of State for Health and Social Care, what assessment she has made of the potential merits of making adrenaline auto injectors more widely available, such as in restaurants and other public places, in the context of the report from the Commission on Human Medicine in 2021.
The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.
To ask the Secretary of State for Health and Social Care, what assessment she has made of the potential impact of the MHRA-NICE aligned pathway that came into force on 1 April 2026 on the pricing of self-funded treatment and medications.
To ask the Secretary of State for Health and Social Care, what assessment she has made of the potential impact of the MHRA-NICE aligned pathway that came into force on 1 April 2026 on the pricing of self-funded treatment and medications.
The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.
To ask the Secretary of State for Health and Social Care, further to the publication of the Government's Final Delivery Plan on Myalgic Encephalomyelitis (ME)/Chronic Fatigue Syndrome on 22 July 2025, when will the one-year update be published.
To ask the Secretary of State for Health and Social Care, further to the publication of the Government's Final Delivery Plan on Myalgic Encephalomyelitis (ME)/Chronic Fatigue Syndrome on 22 July 2025, when will the one-year update be published.
The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.
To ask the Secretary of State for Health and Social Care, what steps her Department is taking to ensure that patients are able to continue to receive hormone replacement treatment if there is an interruption to their shared care agreement.
To ask the Secretary of State for Health and Social Care, what steps her Department is taking to ensure that patients are able to continue to receive hormone replacement treatment if there is an interruption to their shared care agreement.
The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.
To ask the Secretary of State for Health and Social Care, if she will review NHS rules on treatment before surgery for patients with stage 3 melanoma.
To ask the Secretary of State for Health and Social Care, if she will review NHS rules on treatment before surgery for patients with stage 3 melanoma.
The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.
To ask the Secretary of State for Health and Social Care, what steps her Department is taking to improve access to genetic testing for inherited lipid conditions, including familial hypercholesterolaemia, in order to initiate cholesterol management at an early stage for people at greatest risk of cardiovascular disease.
To ask the Secretary of State for Health and Social Care, what steps her Department is taking to improve access to genetic testing for inherited lipid conditions, including familial hypercholesterolaemia, in order to initiate cholesterol management at an early stage for people at greatest risk of cardiovascular disease.
The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.
To ask the Secretary of State for Health and Social Care, hen he plans to respond to Question 4447, 10962 and 15024 tabled by the hon. Member for North Shropshire on 29 May, 17 June and 1 July 2026.
To ask the Secretary of State for Health and Social Care, hen he plans to respond to Question 4447, 10962 and 15024 tabled by the hon. Member for North Shropshire on 29 May, 17 June and 1 July 2026.
I refer the hon. Member to:
the answer my hon. Friend, the former Minister of State for Care, gave on 8 July 2026 to Question 4447;
the answer my hon. Friend, the former Parliamentary Under-secretary of State for Health Innovation and Safety, gave on 12 July 2026 to Question 10962; and
the answer my hon. Friend, the Minister of State for Health, gave on 19 August 2026 to Question 15024.
House adjourned without Question put (Standing Order. 9(7)).
House adjourned without Question put (Standing Order. 9(7)).
To ask the Secretary of State for Health and Social Care, what plans his Department has to establish a national deployment pathway for ambient voice technology, to move beyond repeated local pilots towards system-wide adoption across the NHS.
To ask the Secretary of State for Health and Social Care, what plans his Department has to establish a national deployment pathway for ambient voice technology, to move beyond repeated local pilots towards system-wide adoption across the NHS.
The Department, working with NHS England, is putting in place national support to help National Health Service organisations adopt and scale ambient voice technology (AVT) as appropriate for their respective areas, to help adopt AVT safely and consistently where there is evidence of benefit. NHS England will continue to work with systems, suppliers, and national partners to support adoption at pace where products meet the necessary standards for safety, effectiveness, interoperability, and value for money.
At present, NHS organisations are required to select AVT products from the NHS AVT Self-Certified Supplier Registry. This applies to standalone products or those natively integrated into Electronic Patient Record systems. In order to be allowed onto the registry, suppliers are required to evidence capabilities that show summarisation of output aligned to structured templates and configuration, including suggesting the relevant clinical codes.
While NHS England remains in the process of mobilising a wider programme to support the adoption of AVT, no decision has yet been taken on the eligibility criteria for participating organisations to receive funding, but we will provide further updates in due course.
To ask the Secretary of State for Health and Social Care, what steps the Department is taking with the devolved administrations to increase the number of patients able to participate in commercial clinical trials across the UK.
To ask the Secretary of State for Health and Social Care, what steps the Department is taking with the devolved administrations to increase the number of patients able to participate in commercial clinical trials across the UK.
The Government is committed to ensuring that all patients across the UK have access to cutting-edge clinical trials and innovative, lifesaving treatments, and we are working with the devolved administrations, delivery partners across the health system, and key stakeholders from across the clinical research sector – all under the umbrella of the UK Clinical Research Delivery Programme (UKCRD) – to increase commercial research participation, and make the UK a world leader in clinical trials.
To increase participation by patients across all four nations, we are establishing 21 new Commercial Research Delivery Centres (CRDCs) across the UK, alongside a UK-wide CRDC Network, which will coordinate activity, provide strategic leadership, and support consistency across the centres. The CRDC Network complements established UK-wide infrastructure, including the Experimental Cancer Medicine Centres Network and the UK Clinical Research Facility Network, which support research delivery, strengthen capability, and enable patients across England, Scotland, Wales, and Northern Ireland to access innovative clinical trials.
The Hon Member may also be aware that the National Institute for Health and Care Research provides a UK-wide online service called Be Part of Research, which promotes participation in health and social care research by allowing users to search for relevant studies and register their interest. This makes it easier for people across the UK to find and take part in commercial clinical trials and other health and care research.
In addition to the activity set out above, the Government is taking specific action through the UK Rare Diseases Framework to improve the lives of people living with rare diseases, and last year extended the framework to continue until 2027. The framework sets out four shared priorities for addressing rare diseases across England, Scotland, Wales and Northern Ireland: improving speed of diagnosis; raising awareness of rare conditions with healthcare professionals; coordinating care; and providing access to specialist care and treatments.
Genomic testing and analysis of genomic data is at the heart of the UK Rare Diseases Framework, and the agencies contributing to that activity are taking constant steps to increase interoperability between rare disease registries, genomic data systems, and clinical records held across the four nations, to assist in research, testing and analysis.
To ask the Secretary of State for Health and Social Care, what steps the Department is taking to improve interoperability between rare-disease registries and genomic-data systems across the UK.
To ask the Secretary of State for Health and Social Care, what steps the Department is taking to improve interoperability between rare-disease registries and genomic-data systems across the UK.
The Government is committed to ensuring that all patients across the UK have access to cutting-edge clinical trials and innovative, lifesaving treatments, and we are working with the devolved administrations, delivery partners across the health system, and key stakeholders from across the clinical research sector – all under the umbrella of the UK Clinical Research Delivery Programme (UKCRD) – to increase commercial research participation, and make the UK a world leader in clinical trials.
To increase participation by patients across all four nations, we are establishing 21 new Commercial Research Delivery Centres (CRDCs) across the UK, alongside a UK-wide CRDC Network, which will coordinate activity, provide strategic leadership, and support consistency across the centres. The CRDC Network complements established UK-wide infrastructure, including the Experimental Cancer Medicine Centres Network and the UK Clinical Research Facility Network, which support research delivery, strengthen capability, and enable patients across England, Scotland, Wales, and Northern Ireland to access innovative clinical trials.
The Hon Member may also be aware that the National Institute for Health and Care Research provides a UK-wide online service called Be Part of Research, which promotes participation in health and social care research by allowing users to search for relevant studies and register their interest. This makes it easier for people across the UK to find and take part in commercial clinical trials and other health and care research.
In addition to the activity set out above, the Government is taking specific action through the UK Rare Diseases Framework to improve the lives of people living with rare diseases, and last year extended the framework to continue until 2027. The framework sets out four shared priorities for addressing rare diseases across England, Scotland, Wales and Northern Ireland: improving speed of diagnosis; raising awareness of rare conditions with healthcare professionals; coordinating care; and providing access to specialist care and treatments.
Genomic testing and analysis of genomic data is at the heart of the UK Rare Diseases Framework, and the agencies contributing to that activity are taking constant steps to increase interoperability between rare disease registries, genomic data systems, and clinical records held across the four nations, to assist in research, testing and analysis.
To ask the Secretary of State for Health and Social Care, whether he plans to address the postcode lottery in community glaucoma care across regions in England.
To ask the Secretary of State for Health and Social Care, whether he plans to address the postcode lottery in community glaucoma care across regions in England.
Health services are a devolved matter and arrangements for the commissioning and delivery of primary eye care services differs across the United Kingdom. However, the Department does work closely with our counterparts in the devolved governments to share expertise and identify new opportunities to improve health and social care delivery across the UK, including learning from the different approaches to the delivery of eye care services.
To ask the Secretary of State for Health and Social Care, what steps he is taking to improve community-based glaucoma services across England.
To ask the Secretary of State for Health and Social Care, what steps he is taking to improve community-based glaucoma services across England.
Health services are a devolved matter and arrangements for the commissioning and delivery of primary eye care services differs across the United Kingdom. However, the Department does work closely with our counterparts in the devolved governments to share expertise and identify new opportunities to improve health and social care delivery across the UK, including learning from the different approaches to the delivery of eye care services.
To ask the Secretary of State for Health and Social Care, how many FTE equivalent staff in (a) their Department and (b) each Arm's Length Body it sponsors are dedicated to fulfilment of the Public Sector Equality Duty (PSED); what the (i) annual employment and (ii) total annual cost incurred...
To ask the Secretary of State for Health and Social Care, how many FTE equivalent staff in (a) their Department and (b) each Arm's Length Body it sponsors are dedicated to fulfilment of the Public Sector Equality Duty (PSED); what the (i) annual employment and (ii) total annual cost incurred...
The requested data is not centrally held by the Department, and could only be collated and verified for the purposes of answering this question at disproportionate cost.
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure that ambient voice technology used in the NHS captures structured, coded clinical data at the point of care rather than unstructured free-text notes; what criteria his Department uses to determine which...
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure that ambient voice technology used in the NHS captures structured, coded clinical data at the point of care rather than unstructured free-text notes; what criteria his Department uses to determine which...
The Department, working with NHS England, is putting in place national support to help National Health Service organisations adopt and scale ambient voice technology (AVT) as appropriate for their respective areas, to help adopt AVT safely and consistently where there is evidence of benefit. NHS England will continue to work with systems, suppliers, and national partners to support adoption at pace where products meet the necessary standards for safety, effectiveness, interoperability, and value for money.
At present, NHS organisations are required to select AVT products from the NHS AVT Self-Certified Supplier Registry. This applies to standalone products or those natively integrated into Electronic Patient Record systems. In order to be allowed onto the registry, suppliers are required to evidence capabilities that show summarisation of output aligned to structured templates and configuration, including suggesting the relevant clinical codes.
While NHS England remains in the process of mobilising a wider programme to support the adoption of AVT, no decision has yet been taken on the eligibility criteria for participating organisations to receive funding, but we will provide further updates in due course.
To ask the Secretary of State for Health and Social Care, for each Arm's Length Body (ALB) their Department sponsors, (a) how many people are employed in the following bands of total earnings, or nearest equivalent, (i) under £25,000, (ii) £ 25,001 to £ 35,000, (iii) £35,001 to £50,270, (iv)...
To ask the Secretary of State for Health and Social Care, for each Arm's Length Body (ALB) their Department sponsors, (a) how many people are employed in the following bands of total earnings, or nearest equivalent, (i) under £25,000, (ii) £ 25,001 to £ 35,000, (iii) £35,001 to £50,270, (iv)...
The Department does not routinely collect or publish data on (a) the staffing of arm’s length bodies (ALBs) broken down by earnings band, or (b) what the Hon. Member describes as the ‘total unfunded public sector pension liability’. However, in most cases, the ALBs in question publish their own data on staffing, remuneration, and pension schemes in each body’s annual report and accounts, which are publicly available on GOV.UK.
The Hon. Member can also find details of staff numbers broken down by grade for each ALB, and their overall paybill, in the Workforce Management Information statistics published by the Department each month, the latest edition of which, for June 2026, are available at the following link:
https://www.gov.uk/government/collections/dhsc-workforce-management-information